Abstract
Personalized medicine is revolutionizing oncologic care. Molecular and imaging “fingerprinting”
of cancer through genomics, radiomics, and radiogenomics has allowed for the meticulous
characterization of many forms of malignancy, including primary liver cancers. With
this data, treatments are being developed that precisely target and exploit key variations
in individual tumors. As these methods continue to evolve, interventional oncologists
are well positioned to capitalize on the advances being made. This article will provide
a concise overview of the genomic, radiomic, and radiogenomic research on hepatocellular
carcinoma and intrahepatic cholangiocarcinoma, in addition to discussions on how precision
medicine would relate to interventional oncology.
Keywords
genomics - radiomics - radiogenomics ablation - embolization
